Hikma Pharmaceuticals Plc

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00B0LCW083
GBP
15.14
0.07 (0.46%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Hikma Pharmaceuticals Plc stock-summary
stock-summary
Hikma Pharmaceuticals Plc
Pharmaceuticals & Biotechnology
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 300 products in different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.
Company Coordinates stock-summary
Company Details
1 New Burlington Place , LONDON None : W1S 2HR
stock-summary
Tel: 44 20 73992760
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Said Darwazah
Executive Chairman of the Board
Mr. Sigurdur Olafsson
Chief Executive Officer, Executive Director
Mr. Mazen Darwazah
Executive Vice Chairman of the Board, President of MENA
Mr. Khalid Nabilsi
Chief Financial Officer, Executive Director
Mr. Ali Al-Husry
Non-Executive Director
Mr. Patrick Butler
Senior Non-Executive Independent Director
Mr. John Castellani
Non-Executive Independent Director
Ms. Nina Henderson
Non-Executive Independent Director
Mr. Douglas Hurt
Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 3,506 Million (Mid Cap)

stock-summary
P/E

16.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.26%

stock-summary
Debt Equity

0.50

stock-summary
Return on Equity

13.78%

stock-summary
Price to Book

1.89